Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1456 to 1470 of 1537 results for do not do recommendations

  1. Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

    Discontinued Reference number: GID-TAG387

    Technology appraisal guidance
    Discontinued

  2. UK licensing and technology appraisals

    NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.

  3. Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

    NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

    Medtech innovation briefing
    Published
    19 November 2014

  4. Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults.

    Technology appraisal guidance
    Published
    13 June 2018
    View recommendations

    Sections for TA524

  5. Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections (HTE1)

    Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections....

    Health technology evaluation
    Published
    17 August 2022
    View recommendations

    Sections for HTE1

  6. Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (HTE2)

    Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections....

    Health technology evaluation
    Published
    17 August 2022
    View recommendations

    Sections for HTE2

  7. Peptest for diagnosing gastro‑oesophageal reflux (MIB31)

    NICE has developed a medtech innovation briefing (MIB) on Peptest for diagnosing gastro-oesophageal reflux

    Medtech innovation briefing
    Published
    22 May 2015

  8. Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

    Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

    Evidence summary
    Published
    9 September 2014

  9. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

    Evidence summary
    Published
    22 December 2015

  10. The Oncentra Prostate v4.x for ultrasound‑guided real‑time HDR brachytherapy in men with localised prostate cancer (MIB16)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised

    Medtech innovation briefing
    Published
    16 December 2014

  11. Should NICE's cost-effectiveness thresholds change?

    We explore the ongoing debate around NICE’s cost-effectiveness thresholds and what the future holds.

    News
    Last updated
    14 October 2025

  12. Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

    Discontinued Reference number: GID-TA10566

    Technology appraisal guidance
    Discontinued

  13. Same time decisions on licensing and value - what pharmaceutical companies need to know

    Learn how NICE and MHRA are launching an aligned pathway to accelerate patient access to medicines and provide a more efficient route for industry.

    News
    Last updated
    10 October 2025

  14. Modular updates

    Our modular updates framework ensures flexibility and consistency in updating our manuals and helps prioritise important updates.

  15. Knowledge transfer seminars

    Learn from NICE International, part of the UK's National Institute for Health and Care Excellence, about how to improve your nation's health and wellbeing